Area of research
Cardiology and Cardiovascular Medicine · Pulmonary and Respiratory Medicine
Research interest
Research interests include Acute Myocardial Infarction Research, Respiratory Support and Mechanisms, Cardiovascular Function and Risk Factors, and Heart Failure Treatment and Management.
Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction
Percutaneous vs. surgical revascularization of non-ST-segment elevation myocardial infarction with multivessel disease: the SWEDEHEART registry
Excess Mortality and Loss of Life Expectancy After Myocardial Infarction: A Registry-Based Matched Cohort Study
Prospective benchmarking of an observational analysis in the SWEDEHEART registry against the REDUCE-AMI randomized trial
Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure
Association of anxiety or depression with risk of recurrent cardiovascular events and death after myocardial infarction: A nationwide registry study
Stimulating the Resolution of Inflammation Through Omega-3 Polyunsaturated Fatty Acids in COVID-19: Rationale for the COVID-Omega-F Trial
Long-term mortality in patients with ischaemic heart failure revascularized with coronary artery bypass grafting or percutaneous coronary intervention: insights from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
Incidence, associated outcomes, and predictors of upper gastrointestinal bleeding following acute myocardial infarction: a SWEDEHEART-based nationwide cohort study
Comparison Between Ticagrelor and Clopidogrel in Elderly Patients With an Acute Coronary Syndrome
Association of Pretreatment With P2Y12 Receptor Antagonists Preceding Percutaneous Coronary Intervention in Non–ST-Segment Elevation Acute Coronary Syndromes With Outcomes
Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Previous Myocardial Infarction and Severe Obesity
Temporal trends in bleeding events in acute myocardial infarction: insights from the SWEDEHEART registry
DETermination of the role of OXygen in suspected Acute Myocardial Infarction trial